Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?

Oliver Findling, Johann Sellner

Research output: Journal article (peer-reviewed)Review article

9 Citations (Scopus)

Abstract

Options for disease-modifying therapies in multiple sclerosis have increased over the past two decades. Among these innovations are interferon-β, glatiramer acetate, fumaric acid and dihydroorotate dehydrogenase inhibitors, an antibody targeting the migration of immune cells, a compound that traps immune cells in lymphoid organs by sphingosine 1-phosphate receptor (S1PR) modulation and immune-reconstitution therapies. Second-generation drugs such as pegylated interferon-β, advanced CD20 depleting antibodies, more-specific S1PR modulators and new formulations have been developed to achieve higher efficacy while exhibiting fewer side effects. In this review, we address the shortcomings of the parent drugs, present the pros and cons of the second-generation therapies and summarize upcoming developments in the field of immunotherapy for multiple sclerosis.

Original languageEnglish
Pages (from-to)416-428
Number of pages13
JournalDrug Discovery Today
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 2021

Keywords

  • Animals
  • Drug Development
  • Humans
  • Immunologic Factors/pharmacology
  • Immunosuppressive Agents/pharmacology
  • Immunotherapy/methods
  • Multiple Sclerosis/drug therapy

Fingerprint

Dive into the research topics of 'Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?'. Together they form a unique fingerprint.

Cite this